2[1]Annie W B, Richard A, Jacdos B, et al. Lipid formulations of ampho-tericin B:clinical efficacy and toxicities[J]. Clin Infectious Diseases,1998,27:603-618.
3[2]Andreas H G, Thomas J W. Potential new antifungal agents[J]. Current Opinion in Infectious Diseases,1997,10:449-458.
4[3]Fishman A P. Fishman's pulmonary diseases and disorders[M]. New York:McGraw-Hill,1998.2284-2311.
5[4]John G. Pocket Book of Infectious Disease Therapy[M]. Phila-dephia, USA:Lippincott Williams & Wilkins,2000.158-173.
6[5]Joseph L S, Donglas T P, Boss F, et al. Chronic necrotizing pulmonary aspergillosis-approach to management[J]. Chest,1997,112:541-548.
7[6]Joe W, George S, David M, et al. Practice Guidelines for the manage-ment of patients with histoplasmosis[J]. Clin Infectious Diseases,2000,30:688-695.
8[1]Lacomis JM, Vikhez R, Kusne S, et al. Pulmonary cryptococcosis: radiographic findings in a tertiary care center[ J]. A JR,2000,174:69.
9[2]Kurasawa T, Lkeda N, Sato A, et al. A clinical study of pulmonary cryptococcosis. The Study Group of Respiratory Mycosis in Kyoto[J].Kansenshogaku Zasshi, 1998, 72: 352-357.
10[3]Matsuyama W, Mizoguchi A, Lvami F, et al. Clinical investigation of 15 patients with pulmonary cryptococcosis - clinical comparison of HTLV-1 carriers and noncarriers[J]. Nihon Kokyuki Gakkai Zasghi,1999, 37:108- 114.
